Monitoring and Management of Fibrodysplasia Ossificans Progressiva: Current Perspectives [Corrigendu...
Monitoring and Management of Fibrodysplasia Ossificans Progressiva: Current Perspectives [Corrigendum]
About this item
Full title
Author / Creator
Publisher
Dove
Journal title
Language
English
Formats
Publication information
Publisher
Dove
Subjects
More information
Scope and Contents
Contents
Smilde BJ, Botman E, de Ruiter RD, et al. Orthop Res Rev. 2022;14:113-120. On page 118, Treatments in Development section, 2nd paragraph, 2nd sentence "The only drug in development for FOP in this medication class is Palovarotene, a retinoic acid-gamma (RAR-γ) antagonist" should read "The only drug in development for FOP in this medication class is...
Alternative Titles
Full title
Monitoring and Management of Fibrodysplasia Ossificans Progressiva: Current Perspectives [Corrigendum]
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_a3256693b84e4a98a71e84d1e77d3e22
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a3256693b84e4a98a71e84d1e77d3e22
Other Identifiers
ISSN
1179-1462
E-ISSN
1179-1462
DOI
10.2147/ORR.S373122
